Skip to main content

Arup to Offer Predictive Bio's Bladder Cancer Dx

NEW YORK (GenomeWeb News) – Predictive Biosciences will offer its molecular diagnostic bladder cancer tests to Arup Laboratories' national network of clients under a deal announced today.

The non-exclusive agreement grants Salt Lake City-based Arup the rights to offer Predictive Bio's CertNDx Bladder Cancer Assays to hospitals, healthcare providers, academic medical centers, and military and government facilities around the country. Arup's clients will be able to order the test through the reference laboratory, while Predictive Bio will run the diagnostic testing in its CAP and CLIA-certified laboratory.

The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test for the evaluation of patients with hematuria and for the monitoring of bladder cancer recurrence after treatment. It stratifies patients based on their likelihood of bladder cancer and is also available as a tissue-based prognostic test for molecular grading.

"We believe this alliance will greatly expand the availability of our bladder cancer products to a wider network of leading medical facilities that can benefit from CertNDx testing," Predictive Bio CEO Pierre Cassigneul said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.